Recently, President Trump signed a “most-favored nation” executive order on drug prices with a claim that it would force pharmaceutical companies to lower U.S. prescription costs to match those abroad. As a result, the White House announced a deal with Pfizer to lower drug prices and a new direct-to-consumer website dubbed “TrumpRx.”

But none of these actions will lead to substantial savings for the government or patients. This is all just political theater — in fact, pharmaceutical stocks rose after the order was signed and significantly rose again after the announcement with Pfizer.

If Trump truly wanted to lower costs, he’d push a real most-favored nation policy that aligns U.S. generic drug entry with other countries’ timelines. True market competition would bring down price

See Full Page